Icon Bioscience Achieves Key Milestone With IBI-10090 Advancing Through Phase 3 Studies; Drug Targets Medical Need For Long-Acting Treatment Of Inflammation Post Cataract Surgery

SUNNYVALE, Calif.--(BUSINESS WIRE)--Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today reported that IBI-10090, the Company’s lead pipeline product, is in a pivotal Phase 3 study as a sustained-release therapy for inflammation associated with cataract surgery.

Help employers find you! Check out all the jobs and post your resume.